To understand the immunogenicity of Covisheild vaccine in patients with rheumatological disease by discontinuing methotrexate temporarily after taking second dose of vaccine
Not Applicable
- Registration Number
- CTRI/2021/07/035307
- Lead Sponsor
- Centre for Arthritis and Rheumatism Excellence CARE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Inclusion Criteria
Patient above 18 years of age.
Patients willing to give consent for the study
Patients with a prior diagnosis of Autoimmune Rheumatic Disease and on methotrexate ,
stable dose for atleast the past 2 months
Exclusion Criteria
Patients who had covid-19 infection in the past.
Patients who are not willing for blood sample collection.
Patients with h/o allergy to vaccine components Prior GBS/demyelinating syndromes
Any live vaccine taken within prior 4 weeks or inactivated vaccine in last 2 weeks before study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method